Rockefeller Capital Management
CLRB icon

Rockefeller Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Rockefeller Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed – – 3887
2021
Q4 		$0 Hold
3
– – ﹤0.01% 3790
2021
Q3 		$0 Hold
3
– – ﹤0.01% 3703
2021
Q2 		$1K Buy
+3
New +$1.3K ﹤0.01% 3319

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Rockefeller Capital Management's CLRB Position: Q1 2022 in Review

Rockefeller Capital Management sold out of Cellectar Biosciences (CLRB) in Q1 2022, closing a stake of 3 shares.

Rockefeller Capital Management first reported a position in CLRB in Q2 2021 and held it in 3 quarters. The position peaked at $1K in Q2 2021. 30 funds tracked by Wall St. Rank hold CLRB as of Q1 2022.

  • Rockefeller Capital Management reported no remaining Cellectar Biosciences position as of Q1 2022 after selling out during the quarter.
  • Rockefeller Capital Management sold 3 Cellectar Biosciences shares in Q1 2022.
  • Rockefeller Capital Management first reported a position in Cellectar Biosciences in Q2 2021 and held it in 3 quarters.
  • Rockefeller Capital Management's Cellectar Biosciences position peaked at $1K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2022.

Based on Rockefeller Capital Management's 13F filing for Q1 2022, filed 13 May 2022.